CompletedPhase 3ACTRN12605000058673

Magnesium in Aneurysmal Subarachnoid Haemorrhage

A multi-centre, single blinded, randomised controlled trial of two target ranges for serum magnesium in patients with Subarachnoid Haemorrhage to reduce vasospasm

Sponsor

Pharmalab

Enrollment

190 participants

Start Date

Jan 1, 2010

Study Type

Interventional

Conditions

Subarachnoid Haemorrhage

Summary

Patients had a reduced incidence of vasospasm but the resul was not significant. There was no difference between groupw

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether giving magnesium intravenously can reduce brain damage after an aneurysmal subarachnoid haemorrhage (a type of brain bleed). It is for adults aged 18 and older who have had this type of brain bleed within the past 72 hours. Participation involves receiving magnesium or placebo through an IV drip.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Magnesium sulfate (20ml/hr). The concentration of magnesium will be titrated to the serum magnesium level in order to achieve a serum level of 1.6-2.5mmol/L, in the treatment group.

Locations(1)

Royal Hobart Hospital - Hobart

NSW,TAS, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000058673